Get the Stockscreener App
9.15
1.93%
-0.18
After Hours:
9.15
Omeros Corporation stock is traded at $9.15, with a volume of 363.84K.
It is down -1.93% in the last 24 hours and down -11.25% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$9.33
Open:
$9.51
24h Volume:
363.84K
Relative Volume:
0.37
Market Cap:
$530.24M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-4.867
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
+6.52%
1M Performance:
-11.25%
6M Performance:
+87.50%
1Y Performance:
+135.22%
1-Day Range:
$9.13
$9.7094
1-Week Range:
$8.46
$9.7094
52-Week Range:
$2.612
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
9.15 | 530.24M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Barclays PLC Acquires 51,873 Shares of Omeros Co. (NASDAQ:OMER) - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Up 5.5%Time to Buy? - MarketBeat
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros Co. (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Narsoplimab shows promise in reducing mortality for TA-TMA patients - MSN
Personal Finance - Business Wire
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint - Yahoo Finance
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Jane Street Group LLC Has $231,000 Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
When the Price of (OMER) Talks, People Listen - Stock Traders Daily
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Omeros (NASDAQ:OMER) Stock Price Down 3.1%Time to Sell? - MarketBeat
Geode Capital Management LLC Has $5.32 Million Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Acquired by Barclays PLC - Defense World
Omeros (NASDAQ:OMER) Trading Up 10.3%Time to Buy? - MarketBeat
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
Omeros (NASDAQ:OMER) Shares Gap DownHere's Why - MarketBeat
State Street Corp Has $4.87 Million Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Shares Up 3.6% – Here’s Why - Defense World
MML Investors Services LLC Purchases 3,000 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Stock Price Up 3.6%What's Next? - MarketBeat
When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)? - Yahoo Finance
Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50 - Defense World
HighTower Advisors LLC Increases Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros shares climb as D. Boral Capital initiates with Buy By Investing.com - Investing.com Australia
Omeros shares climb as D. Boral Capital initiates with Buy - Investing.com India
Omeros (NASDAQ:OMER) Now Covered by Analysts at D. Boral Capital - Defense World
retail investors who own 52% along with institutions invested in Omeros Corporation (NASDAQ:OMER) saw increase in their holdings value last week - Simply Wall St
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Omeros (NASDAQ:OMER) Now Covered by D. Boral Capital - MarketBeat
Omeros (NASDAQ:OMER) Hits New 52-Week High – Here’s Why - Defense World
(OMER) Trading Advice - Stock Traders Daily
Wellington Management Group LLP Buys New Shares in Omeros Co. (NASDAQ:OMER) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros Corporation Announces Positive Results for Narsoplimab in Treating Thrombotic MicroangiopathyOn December 19, 2024, Omeros Corporation (NASDAQ: OMER) revealed the outcomes of a primary statistical analysis involving narsoplimab, the comp - Defense World
BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Sets New 12-Month HighStill a Buy? - MarketBeat
Omeros reports survival benefit with narsoplimab in TA-TMA By Investing.com - Investing.com Canada
Stock Of The Day / 12.19.24 / OMER for NASDAQ:OMER by AlexX31 - TradingView
Top Midday Gainers - Marketscreener.com
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Benzinga
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga
Omeros Stock Gains 52% On Successful Trial Results - MarketWatch
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds - Fierce Biotech
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):